STOCK TITAN
  1. Home
  2. LGNXZ

Ligand Pharma (LGNXZ) Stock Price, News & Analysis

LGNXZ OTC Link

Company Description

LGNXZ has gained 200.0% over the past year. Shares last traded at $0.0045.

For FY2025, Ligand Pharma reported revenue of $268.1M with net income of $124.5M and diluted earnings per share of $6.13. The company operates at a net profit margin of 46.4%.

This page collects what Stock Titan holds for LGNXZ, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
-
-
Last updated:
+200.0%
Performance 1 year
-
Market Cap
-
Shares outstanding

Ligand Pharma (LGNXZ) last closed at $0.0045. Over the past 12 months, LGNXZ has gained 200.0%.

See what a $1,000 investment in LGNXZ would be worth today

LGNXZ Rankings

Revenue
$268.1M
#2,589
Piotroski F-Score
4/9
#3,085

Latest News

View All

No recent news available for LGNXZ.

SEC Filings

View All

[8-K/A] A cash-heavy royalty arm at Ligand (NASDAQ: LGND) is loss-making

[4] Ligand Pharmaceuticals (LGND) CFO exercises options and sells 31,641 shares under 10b5-1 plan

[4] Ligand Pharmaceuticals (LGND) director exercises options and sells 7,138 shares

[SCHEDULE 13G] Invesco Ltd. (LGND holder) reports 6.1% beneficial stake in Ligand Pharmaceuticals

[144] LIGAND PHARMACEUTICALS INC SEC Filing

Ligand Pharma has filed 5 recent SEC filings, including 2 Form 4, 1 Form 144, 1 Form 8-K/A, 1 Form SCHEDULE 13G. The most recent filing was submitted on September 2, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all LGNXZ SEC filings →

Financial Highlights

View Full Financials

Ligand Pharma generated $268.1M in revenue in FY2025, operating income reached $41.0M (15.3% operating margin), and net income was $124.5M, reflecting a 46.4% net profit margin. Diluted earnings per share stood at $6.13. The company generated $49.4M in operating cash flow. With a current ratio of 22.23, the balance sheet reflects a strong liquidity position.

$268.1M
Revenue (FY2025)
$124.5M
Net Income (FY2025)
$6.13
Diluted EPS (FY2025)
$49.4M
Operating Cash Flow
46.4%
Net Profit Margin
15.3%
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

Frequently Asked Questions

What is the current quoted price of Ligand Pharma (LGNXZ)?

The current quoted price of Ligand Pharma (LGNXZ) is $0.0045 as of August 31, 2026.

What is the revenue of Ligand Pharma (LGNXZ) stock?

The FY2025 revenue of Ligand Pharma (LGNXZ) is $268.1M, from its most recent completed fiscal year.

What is the net income of Ligand Pharma (LGNXZ)?

The FY2025 net income of Ligand Pharma (LGNXZ) is $124.5M, from its most recent completed fiscal year.

What is the earnings per share (EPS) of Ligand Pharma (LGNXZ)?

The diluted earnings per share (EPS) of Ligand Pharma (LGNXZ) is $6.13 for FY2025, its most recent completed fiscal year. Learn more about EPS .

What is the operating cash flow of Ligand Pharma (LGNXZ)?

The operating cash flow of Ligand Pharma (LGNXZ) is $49.4M. Learn about cash flow.

What is the profit margin of Ligand Pharma (LGNXZ)?

The net profit margin of Ligand Pharma (LGNXZ) is 46.4%. Learn about profit margins.

What is the operating margin of Ligand Pharma (LGNXZ)?

The operating profit margin of Ligand Pharma (LGNXZ) is 15.3%. Learn about operating margins.

What is the current ratio of Ligand Pharma (LGNXZ)?

The current ratio of Ligand Pharma (LGNXZ) is 22.23, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.

What is the operating income of Ligand Pharma (LGNXZ)?

The operating income of Ligand Pharma (LGNXZ) is $41.0M. Learn about operating income.